Table 1.
Distribution of clinical and pathological characteristics by molecular subtype
| Variable | Luminal A (n=113) | Luminal B1 (n=33) | Luminal B2 (n=83) | HER2 (T+) (n=14) | HER2 (T–) (n=31) | Triple negative (n=61) | p-value |
|---|---|---|---|---|---|---|---|
| Age (yr) | |||||||
| ≤ 40 | 31 (27.4) | 9 (27.3) | 17 (20.5) | 2 (14.3) | 4 (12.9) | 15 (24.6) | 0.51 |
| > 40 | 82 (72.6) | 24 (72.7) | 66 (79.5) | 12 (85.7) | 27 (87.1) | 46 (75.4) | |
| Post-menopause | 37 (32.7) | 9 (27.3) | 31 (37.3) | 6 (42.9) | 15 (48.4) | 19 (31.1) | 0.47 |
| cT stage | |||||||
| cT1-2 | 105 (92.9) | 29 (87.9) | 73 (88.0) | 11 (78.6) | 27 (87.1) | 50 (82.0) | 0.16 |
| cT3-4 | 8 (7.1) | 4 (12.1) | 10 (12.0) | 3 (21.4) | 4 (13.0) | 11 (18.0) | |
| cN stage | |||||||
| cN0 | 2 (1.8) | 0 | 1 (1.2) | 0 | 0 | 0 | 0.28 |
| cN1 | 66 (58.4) | 14 (42.4) | 41 (49.4) | 4 (28.6) | 20 (64.5) | 27 (44.3) | |
| cN2-3 | 45 (39.8) | 19 (57.6) | 41 (49.4) | 10 (71.4) | 11 (35.5) | 34 (55.8) | |
| cStage | |||||||
| II | 64 (56.6) | 13 (39.4) | 38 (45.8) | 4 (28.6) | 18 (58.1) | 23 (37.7) | 0.06 |
| III | 49 (43.4) | 20 (60.6) | 45 (54.2) | 10 (71.4) | 13 (41.9) | 38 (62.3) | |
| ypT | |||||||
| ypT0 | 17 (15.0) | 3 (9.1) | 22 (26.5) | 5 (35.7) | 12 (38.7) | 19 (31.1) | 0.01 |
| ypT1 | 61 (54.0) | 12 (36.4) | 39 (47.0) | 6 (42.9) | 13 (41.9) | 27 (44.3) | |
| ypT2-3 | 35 (31.0) | 18 (54.5) | 22 (26.5) | 3 (21.4) | 6 (19.4) | 15 (24.6) | |
| ypN | |||||||
| ypN0 | 27 (23.9) | 14 (42.4) | 33 (39.8) | 4 (28.6) | 17 (54.8) | 33 (54.1) | < 0.01 |
| ypN1 | 56 (49.6) | 7 (21.2) | 26 (31.3) | 6 (42.8) | 10 (32.3) | 17 (27.9) | |
| ypN2-3 | 30 (26.5) | 12 (36.4) | 24 (28.9) | 4 (28.6) | 4 (12.9) | 11 (18.0) | |
| pCR | 12 (10.6) | 2 (6.1) | 16 (19.3) | 3 (21.4) | 11 (35.5) | 14 (23.0) | < 0.01 |
| Histology | |||||||
| IDC | 105 (92.9) | 27 (81.8) | 80 (96.4) | 13 (92.9) | 31 (100) | 61 (100) | < 0.01 |
| Others | 8 (7.1) | 6 (18.2) | 3 (3.6) | 1 (7.1) | 0 | 0 | |
| Histological grade | |||||||
| Well, moderate | 84 (74.3) | 11 (33.3) | 49 (59.0) | 6 (42.9) | 16 (51.6) | 30 (49.2) | < 0.01 |
| Poor | 29 (25.7) | 22 (66.7) | 34 (41.0) | 8 (57.1) | 15 (48.4) | 31 (50.8) | |
| Resection margin | |||||||
| Negative | 100 (88.5) | 27 (81.8) | 70 (84.3) | 14 (100) | 29 (93.5) | 60 (98.4) | < 0.01 |
| Close, positive | 13 (11.5) | 6 (18.2) | 13 (15.7) | 0 | 2 (6.5) | 1 (1.6) |
Values are presented as number (%). HER2 (T+), HER2 with trastuzumab; HER2 (T–), HER2 without trastuzumab; pCR, pathologic complete response; IDC, invasive ductal carcinoma.